Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
posted on
Sep 27, 2024 07:46AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
DATE
|
TIMESTAMP
|
PRICE
|
VOLUME
|
---|---|---|---|
09/25/2024 | 12:03:01 |
0.000001
|
7,680 |
fuzzy you truly believe this trade? Do the math.
7680 X .000001 = .007 cents.
Bogus trade! A fictitious trade! Manipulation by a broker on the OTC!
Koo